InnoCare Pharma
百济神州(北京)
Executive Summary
InnoCare Pharma appears to be confused with BeiGene in this profile, as the Chinese name suggests BeiGene Beijing operations. If this is indeed a separate InnoCare entity, limited public information suggests a Beijing-based biotech with unclear corporate structure. BIOSECURE risk appears manageable given clear designation, but due diligence should verify actual corporate identity and structure. Limited visibility into pipeline and leadership raises questions about deal readiness.
Structure: Corporate structure is unclear from available data, requiring immediate clarification of whether this is a standalone entity or related to larger pharma groups. The Beijing location and limited public information suggest this may be a subsidiary or affiliate of a larger organization, necessitating thorough corporate structure mapping during due diligence.
BIOSECURE Risk
Entity shows clear BIOSECURE status and is not designated under BCC categories, indicating lower regulatory risk for US partnerships
Key Exposures:
- •Beijing headquarters location
- •Potential undisclosed government connections
- •Unclear corporate ownership structure
Mitigation: No specific BIOSECURE mitigation activities identified due to limited corporate disclosure
BD Intelligence
Therapeutic Areas:
Recent Deals: No recent deal activity identified in available data
Approach: Conduct preliminary corporate identity verification before initiating formal BD discussions, focusing on pipeline disclosure and leadership introductions
Red Flags
- ⚠Limited corporate transparency
- ⚠Unclear relationship to other pharma entities
- ⚠No visible pipeline or leadership information
- ⚠Potential entity misidentification in database
Quick Facts
- Key People
- 0
- Subsidiaries
- 0
- CDMO/CRO Subs
- 0
- Genomics Subs
- 0
- Direct BIOSECURE
- 0
- Corp Events
- 0
- Gov-Connected
- 0
- Clinical Trials
- 0
- Publications
- 0
- Drug Molecules
- 0
- Relationships
- 0
Sources & Methodology
Clinical trials data: ClinicalTrials.gov API v2 (0 trials linked to this entity)
SEC BIOSECURE filings: EDGAR EFTS full-text search (850+ filings from 230 companies)
Publications: Europe PMC API (0 publications indexed)
Drug molecules: ChEMBL database (European Bioinformatics Institute)
Financial data: East Money (东方财富) datacenter API / CNINFO (巨潮资讯网)
Corporate structure: Company official filings, HKEX/SSE/SZSE disclosures
Executive profiles: Company official biographies, SEC filings, LinkedIn (where verified)
Data is collected from public sources and updated weekly. Corporate intelligence is verified by a native Mandarin-speaking analyst against Chinese-language primary sources including Tianyancha (天眼查), GSXT (国家企业信用信息公示系统), and CNINFO (巨潮资讯网). This is not financial or legal advice.